Search Submit Your Manuscript

Become A Member

  1. Home
  2. May 2024
  3. 13.Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Disease: A Clinical Based Study
Article Image
Admin

13.Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Disease: A Clinical Based Study

Saeed Anwar1, Fawad Majid2, Farhan Tariq4, Sajid Ali Ahmad3 and Muhammad Ali5

ABSTRACT

Objective: In the current study, we aimed to find the safety and efficacy of semaglutide in patients having NAFLD.

Study Design: A clinical based study

Place and Duration of Study: This study was conducted at the Department of Medicine, DHQ Hospital, Jhelum Pakistan from 14th February 2020 to 20th November 2022.

Methods: Baseline characteristics of the patients suspected of NAFLD were assessed which included liver-function tests, BMI, age, gender distribution, body weight, lipid profile, and diabetes-related markers. Blood profiling by Mindray protocol was performed and ultrasonography was also done.

Results: Significant improvements were observed in triglycerides (p = 0.001), LDL cholesterol (p = 0.001), HDL cholesterol (p = 0.03), body weight (p = 0.04), fasting plasma glucose (<0.001), BMI (p = 0.0001) and HbA1c (p = 0.42). Reductions in ALT (p = 0.0001) and AST (p = 0.13) in liver function tests. An decrease in triglyceride level (169±6 mg/dl to 163±2 mg/dl) and LDL cholesterol (102±4 mg/dl to 98±3 mg/dl) was observed through Semaglutide, while there was a decrease in HDL cholesterol (43±2 mg/dl to 41±1 mg/dl). A reduction in the level of ALT (27±3 U/L to 21±1 U/L) was observed. Body BMI (38±2 kg/m² to 32.5±1.0 kg/m²) and body weight (225±6 kg to 90.8±1.2 kg) were reduced after treating with semaglutide compared to baseline. Glycemic control was improved through HbA1c levels improvement (5.9±0.1% to 5.5±0.3%), while an increase in fasting glucose level (64±5 mg/dl to 102±5 mg/dl) was observed with Semaglutide.

Conclusion: Semaglutide provides a therapeutic option for NAFLD, but still, collaborative efforts and modifications in lifestyle are required to lessen this burden on human health. An effective improvement was observed in different parameters by comparing Semaglutide activity with baseline measures.

Key Words: Non-alcoholic fatty liver disease, Blood Profiling, Semaglutide treatment

Citation of article: Anwar S, Majid F, Tariq F, Ahmad SA, Ali M. Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Disease: A Clinical Based Study. Med Forum 2024;35(5):60-64. doi:10.60110/medforum.350513.